Syndecan-1-Dependent Regulation of Heparanase Affects Invasiveness, Stem Cell Properties, and Therapeutic Resistance of Caco2 Colon Cancer Cells.
cancer stem cells
colon cancer
heparan sulfate
heparanase
proteoglycan
syndecan
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
05
02
2020
accepted:
21
04
2020
entrez:
2
6
2020
pubmed:
2
6
2020
medline:
2
6
2020
Statut:
epublish
Résumé
The heparan sulfate proteoglycan Syndecan-1 binds cytokines, morphogens and extracellular matrix components, regulating cancer stem cell properties and invasiveness. Syndecan-1 is modulated by the heparan sulfate-degrading enzyme heparanase, but the underlying regulatory mechanisms are only poorly understood. In colon cancer pathogenesis, complex changes occur in the expression pattern of Syndecan-1 and heparanase during progression from well-differentiated to undifferentiated tumors. Loss of Syndecan-1 and increased expression of heparanase are associated with a change in phenotypic plasticity and an increase in invasiveness, metastasis and dedifferentiation. Here we investigated the regulatory and functional interplay of Syndecan-1 and heparanase employing siRNA-mediated silencing and plasmid-based overexpression approaches in the human colon cancer cell line Caco2. Heparanase expression and activity were upregulated in Syndecan-1 depleted cells. This increase was linked to an upregulation of the transcription factor Egr1, which regulates heparanase at the promoter level. Inhibitor experiments demonstrated an impact of focal adhesion kinase, Wnt and ROCK-dependent signaling on this process. siRNA-depletion of Syndecan-1, and upregulation of heparanase increased the colon cancer stem cell phenotype based on sphere formation assays and phenotypic marker analysis (Side-population, NANOG, KLF4, NOTCH, Wnt, and TCF4 expression). Syndecan-1 depletion increased invasiveness of Caco2 cells
Identifiants
pubmed: 32477959
doi: 10.3389/fonc.2020.00774
pmc: PMC7240066
doi:
Types de publication
Journal Article
Langues
eng
Pagination
774Informations de copyright
Copyright © 2020 Katakam, Pelucchi, Cocola, Reinbold, Vlodavsky, Greve and Götte.
Références
Jpn J Cancer Res. 2001 Oct;92(10):1074-81
pubmed: 11676858
Semin Cancer Biol. 2012 Oct;22(5-6):361-8
pubmed: 22613485
FEBS J. 2013 May;280(10):2294-306
pubmed: 23374281
Cytometry A. 2012 Apr;81(4):284-93
pubmed: 22311742
Exp Ther Med. 2011 Mar 1;2(2):229-238
pubmed: 21442027
Oncology. 2005;68(4-6):306-13
pubmed: 16020957
Cancer Res. 2006 Nov 1;66(21):10233-7
pubmed: 17079438
Cancer Res. 2015 Sep 15;75(18):3946-57
pubmed: 26249176
Lab Invest. 2003 May;83(5):613-22
pubmed: 12746471
Cancer Res. 2003 Dec 15;63(24):8821-6
pubmed: 14695198
FEBS J. 2014 Nov;281(22):5009-22
pubmed: 25168226
Cell. 2008 May 16;133(4):704-15
pubmed: 18485877
Trends Biochem Sci. 2005 Nov;30(11):611-21
pubmed: 16185874
Mod Pathol. 2006 Jun;19(6):878-88
pubmed: 16607375
Mol Cancer Ther. 2017 Aug;16(8):1705-1716
pubmed: 28716813
PLoS One. 2013 Dec 31;8(12):e85737
pubmed: 24392029
J Biol Chem. 2013 Apr 26;288(17):12366-75
pubmed: 23504323
Anticancer Res. 2010 Jun;30(6):2041-8
pubmed: 20651349
Int J Cancer. 2012 Sep 15;131(6):E884-96
pubmed: 22573479
Semin Cancer Biol. 2020 May;62:48-67
pubmed: 31336150
FASEB J. 2003 Jun;17(9):1015-25
pubmed: 12773484
Gynecol Oncol. 2007 Feb;104(2):311-9
pubmed: 17030350
J Clin Invest. 2011 May;121(5):1709-21
pubmed: 21490396
Semin Cancer Biol. 2010 Jun;20(3):153-60
pubmed: 20619346
Cancer Res. 2011 Apr 1;71(7):2772-80
pubmed: 21447736
FASEB J. 2005 Feb;19(2):211-21
pubmed: 15677344
Blood. 2007 Jun 1;109(11):4914-23
pubmed: 17339423
Biochemistry. 2005 Sep 20;44(37):12355-61
pubmed: 16156648
Biochemistry. 2000 Dec 26;39(51):15659-67
pubmed: 11123890
Food Funct. 2017 Aug 1;8(8):2857-2864
pubmed: 28726915
BMC Cell Biol. 2017 Dec 08;18(1):34
pubmed: 29216821
Jpn J Cancer Res. 2001 Oct;92(10):1062-73
pubmed: 11676857
Int J Cancer. 2014 Dec 1;135(11):2579-92
pubmed: 24752740
Nat Rev Cancer. 2008 Oct;8(10):755-68
pubmed: 18784658
BMC Cancer. 2018 Jun 25;18(1):687
pubmed: 29940912
Drug Resist Updat. 2016 Nov;29:54-75
pubmed: 27912844
Br J Cancer. 1996 Aug;74(3):423-31
pubmed: 8695359
Int J Biochem Cell Biol. 2006;38(12):2018-39
pubmed: 16901744
J Biol Chem. 2005 Oct 21;280(42):35136-47
pubmed: 16093249
Am J Pathol. 2000 Oct;157(4):1167-75
pubmed: 11021821
Mol Cancer. 2017 Mar 7;16(1):57
pubmed: 28270211
Biochem Pharmacol. 2013 May 15;85(10):1424-32
pubmed: 23466421
BMC Cancer. 2008 Jun 30;8:185
pubmed: 18590537
FEBS J. 2011 Jan;278(1):16-27
pubmed: 21087457
Breast Cancer Res. 2009;11(4):R46
pubmed: 19589136
FEBS J. 2013 May;280(10):2216-27
pubmed: 23289672
Nat Rev Cancer. 2005 Sep;5(9):744-9
pubmed: 16148886
BMC Cancer. 2015 Oct 20;15:742
pubmed: 26482785
Int J Cancer. 2011 Oct 15;129(8):2042-9
pubmed: 21165952
Nat Rev Cancer. 2015 Jul;15(7):409-25
pubmed: 26105538
Curr Med Chem. 2017;24(26):2860-2886
pubmed: 28215163
J Cell Physiol. 2009 Feb;218(2):294-303
pubmed: 18844239
Biomed Res Int. 2013;2013:517237
pubmed: 24294611
Matrix Biol. 2018 Nov;73:105-121
pubmed: 29499357
Biochim Biophys Acta. 2013 Feb;1830(2):2496-508
pubmed: 23079585
Eur J Cancer. 2004 Jun;40(9):1373-82
pubmed: 15177497
FEBS J. 2019 Aug;286(15):2870-2882
pubmed: 31230410
Cancer Cell. 2013 Oct 14;24(4):481-98
pubmed: 24035453
Cancer Res. 2000 Sep 1;60(17):4761-6
pubmed: 10987283
J Cancer Res Clin Oncol. 2005 Apr;131(4):229-37
pubmed: 15625607